The phase 3 study, published online in The Lancet, is the latest to show the effectiveness of everolimus in slowing the cell growth that is overactive in patients with TSC. (sciencedaily.com)
In testing on two mouse cell lines, the drug combination reduced the viability of cancer cells by about 50 percent when compared with everolimus alone, according to the findings. (sciencedaily.com)
One idea was finding something to make the antitumor drug everolimus more effective. (sciencedaily.com)